FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$124M
This Quarter Return
-0.85%
1 Year Return
-24.36%
3 Year Return
+1.86%
5 Year Return
+16.17%
10 Year Return
–
AUM
$305M
AUM Growth
+$305M
(+6%)
Cap. Flow
+$36.8M
Cap. Flow
% of AUM
12.05%
Top 10 Holdings %
Top 10 Hldgs %
82.2%
Holding
22
New
6
Increased
3
Reduced
4
Closed
1
Top Buys
| 1 |
Replimune Group
REPL
|
$19.8M |
| 2 |
Omeros
OMER
|
$8.69M |
| 3 |
OPTN
OptiNose
OPTN
|
$6.59M |
| 4 |
Xenon Pharmaceuticals
XENE
|
$5.09M |
| 5 |
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
|
$2.79M |
Top Sells
| 1 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$3.55M |
| 2 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
$2.24M |
| 3 |
ALDR
Alder Biopharmaceuticals, Inc.
ALDR
|
$2.16M |
| 4 |
Ascendis Pharma
ASND
|
$1.77M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
$729K |
Sector Composition
| 1 | Healthcare | 91.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Insmed
INSM
$28.8B
| $36.4M | 11.94% | 1,800,587 | – | – |
|
|
MYOK
2
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $33.3M | 10.93% | 511,244 -54,511 | -10% | -$3.55M |
|
|
BHVN
3
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $32M | 10.48% | 851,200 | – | – |
|
|
IMMU
4
DELISTED
Immunomedics Inc
IMMU
| $25.7M | 8.41% | 1,231,543 | – | – |
|
5
Arbutus Biopharma
ABUS
$711M
| $25.3M | 8.29% | 2,676,825 +25,000 | +0.9% | +$236K |
|
|
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
| $22.4M | 7.35% | 2,023,369 | – | – |
|
|
7
Rhythm Pharmaceuticals
RYTM
$6.85B
| $20.3M | 6.66% | 696,903 -25,000 | -3% | -$729K |
|
|
8
Replimune Group
REPL
$422M
| $19.8M | 6.49% | +1,229,656 | New | +$19.8M |
|
|
OPTN
9
DELISTED
OptiNose
OPTN
| $18.1M | 5.94% | 1,458,545 +530,000 | +57% | +$6.59M |
|
|
10
Ascendis Pharma
ASND
$11.8B
| $17.4M | 5.7% | 245,424 -25,000 | -9% | -$1.77M |
|
|
ALDR
11
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $16.7M | 5.46% | 1,000,919 -130,000 | -11% | -$2.16M |
|
|
12
Omeros
OMER
$283M
| $8.69M | 2.85% | +356,000 | New | +$8.69M |
|
13
Aclaris Therapeutics
ACRS
$209M
| $7.69M | 2.52% | 529,551 | – | – |
|
|
EIDX
14
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $5.24M | 1.72% | 525,000 +279,918 | +114% | +$2.79M |
|
|
15
Xenon Pharmaceuticals
XENE
$2.98B
| $5.09M | 1.67% | +385,714 | New | +$5.09M |
|
16
Arcus Biosciences
RCUS
$1.13B
| $4.11M | 1.35% | 295,000 | – | – |
|
|
GRTS
17
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $2.49M | 0.82% | +175,000 | New | +$2.49M |
|
18
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $2.41M | 0.79% | 94,477 | – | – |
|
19
Crinetics Pharmaceuticals
CRNX
$2.92B
| $1.42M | 0.47% | +49,600 | New | +$1.42M |
|
20
uniQure
QURE
$896M
| $388K | 0.13% | 10,650 | – | – |
|
|
VRNA
21
Verona Pharma
VRNA
$9.16B
| $104K | 0.03% | +8,302 | New | +$104K |
|
|
TCDA
22
DELISTED
Tricida, Inc. Common Stock
TCDA
| – | – | -75,000 | Closed | -$2.24M |
|